POLA-R-CHP
Phase 2Small molecule
POLA-R-CHP is one of 53 small molecule programs targeting Diffuse Large B-Cell Lymphoma. It is currently in Phase 2.
2
Indications
4
Total Trials
4
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
332 competitors in Diffuse Large B-Cell Lymphoma
#DrugCompanyPhaseTrials
1Adriamycin
PfizerPhase 3
Rituxan
RochePhase 3
Gemzar
Johnson & JohnsonPhase 3
Gazyva
RochePhase 3
Eloxatin
TevaPhase 3
Rayos
RRoxane Laboratories
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
COLUMVI
RochePhase 3
Cytosar
TevaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for POLA-R-CHP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- FFudan University